Christopher Bruhn

Christopher Bruhn is a seasoned expert in computational biology with extensive experience in drug discovery and data analysis. Currently serving as Team Lead in Computational Biology at Evotec since December 2021, Christopher oversees projects related to Hit ID, Target Validation, and Drug Safety, while also pioneering solutions for big data analysis and automation technologies. Prior to this role, Christopher contributed as a Postdoctoral Research Scientist at IFOM, focusing on the interplay between DNA damage response and metabolism. Notable research experiences also include visiting positions at NCBS and the National Institutes of Health, and a foundational role at the Fritz Lipmann Institute, where Christopher investigated DNA damage response mechanisms. Academic credentials include a PhD in Molecular Biology and a Diploma in Biochemistry and Molecular Biology from Friedrich Schiller University Jena, supplemented by studies at Umeå University. Christopher's early career involved programming for a web design company, showcasing a diverse skill set that combines scientific inquiry with technological expertise.